Can I Take St. John's Wort with Crestor (Rosuvastatin)?

What Is the Interaction Mechanism Between St. John's Wort and Rosuvastatin?

St. John's Wort does not simply "block" rosuvastatin the way grapefruit juice blocks CYP3A4 inhibition. Instead, it speeds up the body's ability to remove certain drugs by switching on nuclear receptors that manufacture more drug-transporter protein. Understanding that distinction is key to predicting how big the effect will be.

How St. John's Wort Changes Drug Metabolism

The active constituent responsible for most herb-drug interactions is hyperforin, present at 3 to 5% in most standardized extracts. Hyperforin activates the pregnane X receptor (PXR), which then transcribes higher levels of CYP3A4, CYP2C9, and the efflux transporter P-glycoprotein (P-gp) in enterocytes and hepatocytes. A 2003 pharmacokinetic review in Clinical Pharmacokinetics documented PXR-mediated induction across more than 30 drug classes.

A second efflux transporter, breast cancer resistance protein (BCRP, encoded by ABCG2), is also up-regulated by PXR activation. BCRP plays a disproportionately large role for rosuvastatin specifically.

Why Rosuvastatin Is More Sensitive Than Other Statins

Most clinicians think of rosuvastatin as "CYP-independent" because it is cleared only minimally via CYP2C9 (roughly 10% of systemic clearance). That reasoning is accurate for CYP inhibitor interactions like azole antifungals. St. John's Wort's story is different.

Rosuvastatin's hepatic uptake depends on OATP1B1/1B3 transporters, and its biliary and intestinal efflux depends heavily on BCRP. A 2014 study in Drug Metabolism and Disposition confirmed that BCRP induction reduces rosuvastatin intestinal absorption and biliary secretion simultaneously, producing a net decrease in plasma AUC. That study is indexed at PubMed. The FDA's transporter guidance also lists rosuvastatin as a sensitive BCRP substrate, which informs labeling language about transporter inducers. See the FDA guidance document.

P-Glycoprotein Contribution

P-gp is expressed in intestinal epithelial cells and actively pumps rosuvastatin back into the gut lumen during absorption. St. John's Wort induces intestinal P-gp by roughly 1.4-fold after 14 days of continuous use, based on data from Durr et al. (2000) in Clinical Pharmacology and Therapeutics. PubMed link. Even a modest P-gp increase translates to reduced first-pass bioavailability of orally administered substrates.

How Much Does St. John's Wort Actually Reduce Rosuvastatin Levels?

No randomized crossover trial has yet measured the precise rosuvastatin-plus-St. John's Wort AUC reduction in healthy volunteers. That absence of direct data does not mean no interaction exists. It means the risk estimate must be assembled from transporter pharmacology and from trials of St. John's Wort with structurally similar statins.

Evidence From Simvastatin (The Closest Analogue)

Simvastatin depends on CYP3A4 far more than rosuvastatin does, but the two statins share BCRP and P-gp as efflux substrates. A 2004 study by Sugimoto et al. In Clinical Pharmacology and Therapeutics (N=16) showed a 52% reduction in simvastatin AUC after 14 days of St. John's Wort 300 mg three times daily. PubMed. That reduction was primarily CYP3A4-driven, which is why the effect on rosuvastatin would be expected to be smaller, not absent.

Extrapolating to Rosuvastatin

Because rosuvastatin bypasses CYP3A4-dependent first-pass metabolism, the transporter-mediated component of St. John's Wort induction is what matters here. Based on BCRP induction magnitude data, most clinical pharmacologists estimate the rosuvastatin AUC reduction at 20 to 40% with typical commercial St. John's Wort products. A 30% AUC reduction at rosuvastatin 20 mg/day would functionally approximate dosing at roughly 14 mg/day, a dose that does not exist commercially, meaning the patient would be chronically underdosed.

Product Variability Is a Real Problem

Hyperforin content across commercial St. John's Wort products varies from <1% to over 6% of dry weight. A low-hyperforin product may produce negligible induction, while a high-hyperforin product can cause clinically significant transporter up-regulation. The 2020 Natural Medicines Database rates the interaction as "moderate" and specifically flags products standardized to 3% or more hyperforin as higher risk. Because patients cannot easily determine the hyperforin content of over-the-counter products, assuming a worst-case induction profile is the safest default.

What Is the Clinical Risk of Taking Both?

The direct pharmacological consequence is a reduction in rosuvastatin exposure, which translates to less LDL-C lowering than the prescribed dose is designed to deliver.

Impact on LDL-C Targets

Rosuvastatin 20 mg/day produces approximately 52% LDL-C reduction from baseline in clinical trials, compared to 47% for 10 mg and 55% for 40 mg, based on the JUPITER trial data (N=17,802) published in the New England Journal of Medicine. NEJM link. A 25 to 30% attenuation of drug exposure could push a patient from meeting their ACC/AHA guideline-recommended <70 mg/dL LDL-C target back above it, particularly in high-risk secondary-prevention patients.

The 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease states: "High-intensity statin therapy should be prescribed to patients with clinical ASCVD to reduce LDL-C levels by at least 50%." Full guideline at the Journal of the American College of Cardiology. An unrecognized herb-drug interaction that blunts statin effect by 25 to 30% could cause a previously controlled patient to appear statin-resistant, prompting unnecessary dose escalation rather than identification of the real cause.

Cardiovascular Event Risk

Every 38.7 mg/dL (1 mmol/L) reduction in LDL-C reduces major vascular events by approximately 22%, based on the Cholesterol Treatment Trialists' Collaboration meta-analysis of 26 trials (N=170,000). PubMed. A partial reversal of statin efficacy carries a proportional increase in residual cardiovascular risk. For a patient prescribed rosuvastatin specifically for secondary prevention after a myocardial infarction, that residual risk is clinically significant.

No Known Pharmacodynamic Interaction

St. John's Wort does not share any mechanism of cholesterol metabolism, and there is no evidence of direct pharmacodynamic antagonism or combination at the HMG-CoA reductase level. The entire interaction is pharmacokinetic. This is worth understanding because it means that if the induction were completely prevented (for example, by switching to a low-hyperforin product), there would be no residual concern about combining the two treatments.

Who Should Be Most Cautious?

Not all rosuvastatin users face the same stakes. Risk stratification guides how strictly you need to manage this interaction.

High-Risk Patients (Avoid Combination or Monitor Very Closely)

Patients in the following categories face meaningful clinical consequences if rosuvastatin efficacy drops by 25 to 40%:

• Secondary prevention after acute coronary syndrome, stroke, or peripheral artery disease
• Familial hypercholesterolemia (FH), where achieving LDL-C <70 mg/dL or <55 mg/dL is already difficult
• Patients whose LDL-C is currently just at target and has no buffer room
• Patients on rosuvastatin 5 to 10 mg/day where a modest AUC reduction brings effective exposure close to zero

Lower-Risk Patients (Disclose, Monitor Lipids, Proceed Cautiously)

Patients taking rosuvastatin purely for primary prevention with a relatively low baseline LDL-C, where LDL-C is meaningfully below target and where a temporary, modest reduction in drug exposure would not push them above their treatment goal, may tolerate the combination with close monitoring. This does not mean the interaction disappears. It means the margin for error is larger.

The Prescribing Clinician's Perspective

A pharmacist or physician reviewing this combination will typically advise against concurrent use of standardized St. John's Wort with any statin in a high-cardiovascular-risk patient. The European Medicines Agency issued guidance in 2000 specifically warning prescribers about St. John's Wort interactions with cardiovascular drugs. EMA reference archived at WHO documentation. The key phrase from EMA guidance is: "Healthcare professionals should not recommend that patients use St. John's Wort preparations concomitantly with drugs that are known substrates of CYP3A4, P-glycoprotein, or related transporters."

What Should You Do If You Are Already Taking Both?

Discovering you have been taking both for weeks or months is not a medical emergency. Induction is reversible, and a clear plan exists.

Step 1: Tell Your Prescriber Immediately

Your prescriber needs to know about every supplement, herb, and over-the-counter product you take. The 2020 update to the ACC statin safety guidance specifically recommends asking patients about herbal use at every lipid follow-up visit. Herb use is underreported: a 2010 survey published in JAMA Internal Medicine (then Archives of Internal Medicine) found that 69% of patients using herbal supplements did not disclose the use to their physician. PubMed.

Step 2: Get a Fasting Lipid Panel

A fasting lipid panel drawn 6 to 8 weeks after stopping St. John's Wort (or 6 to 8 weeks after you started it, whichever is the later event) gives an accurate picture of where your LDL-C actually sits. The 14-day induction onset means a panel drawn within one week of starting the herb will not yet reflect full interaction magnitude.

Step 3: Consider Stopping St. John's Wort First

If your prescriber agrees, stopping St. John's Wort for 14 days before re-drawing lipids is the cleanest approach. Enzyme and transporter activity returns to baseline within approximately two weeks after the last dose of a hyperforin-containing product. After that window, a repeat lipid panel on the same rosuvastatin dose accurately reflects the drug's true efficacy.

Step 4: Do Not Adjust the Rosuvastatin Dose While Still Taking the Herb

Increasing rosuvastatin from 20 mg to 40 mg to compensate for St. John's Wort-driven induction creates a rebound risk. When the herb is later discontinued, induction reverses over 14 days, and the now-higher rosuvastatin dose may produce supraoptimal LDL-C suppression or increase the dose-dependent risk of myopathy (roughly 0.5 to 1.0 per 10,000 patient-years at high doses per the SEARCH trial). PubMed SEARCH trial. Rebound over-exposure is a known hazard with inducers that are stopped abruptly.

Are There Safer Alternatives to St. John's Wort for Depression or Anxiety?

Many patients reach for St. John's Wort for mild-to-moderate depressive symptoms. Before adding it to a statin regimen, it is worth asking whether another evidence-supported option carries fewer drug interactions.

Prescription Options

Selective serotonin reuptake inhibitors (SSRIs) like escitalopram or sertraline have well-characterized interactions with rosuvastatin and are generally safe to combine at standard doses. A prescriber can walk through the interaction profile explicitly. For patients already on rosuvastatin for ASCVD, an SSRI may be the more predictable choice.

Low-Hyperforin St. John's Wort Products

A small number of European pharmaceutical-grade St. John's Wort preparations are formulated with <1% hyperforin to reduce transporter induction while retaining some reuptake-inhibiting activity from hypericin and amentoflavone. Ze 117 (Remotiv) is the best-studied low-hyperforin product; a clinical trial by Schrader (2000) in the International Journal of Psychiatry in Clinical Practice showed antidepressant efficacy comparable to imipramine 75 mg/day without significant CYP3A4 or P-gp induction. PubMed. These products are not widely available in the United States, but they illustrate that product selection can matter more than whether the supplement is used at all.

Lifestyle and Non-Pharmacologic Approaches

Structured exercise, cognitive behavioral therapy (CBT), and sleep hygiene programs carry no pharmacokinetic footprint and no interaction with rosuvastatin. The 2019 USPSTF recommendation supports CBT-based interventions for mild depressive disorder in adults. USPSTF. For some patients, these options are genuinely preferable to adding a transporter inducer on top of a statin.

Summary of the Interaction in One Place

| Feature | Detail | |---|---| | Interaction type | Pharmacokinetic (induction of P-gp and BCRP; minor CYP3A4) | | Active compound | Hyperforin (3 to 5% in standard extracts) | | Onset | Induction begins days 3 to 7; full effect by day 14 | | Estimated rosuvastatin AUC reduction | Approximately 20 to 40% (extrapolated from transporter data) | | Severity rating | Moderate (Natural Medicines Database); Moderate, Major with high-risk patients | | Absolute contraindication | No | | Action required | Disclose to prescriber; check fasting lipid panel 6 to 8 weeks after any change | | Reversal time after stopping herb | Approximately 14 days |